Antithrombotic and Anticoagulation
- Sub endothelium
- Pro-thrombotic
- Endothelium
- Highly anti-thrombotic.
- [As long as endothelium is intact - Clotting does not occur]
- Secretes
- Prostacyclin
- Nitric oxide
- NO is the endothelium derived relaxing factor.
- ADPase
- Anticoagulant effect of endothelium is by:
- Thrombomodulin
- Heparin like molecule
- Tissue factor pathway inhibitor
Mechanism | Key points |
Thrombomodulin | Produced by endothelium |
ㅤ | Prominent in cerebral circulation |
ㅤ | Binds thrombin |
ㅤ | Activates Protein C & S ↳ Inactivate Factors 5 & 8 |
ㅤ | Mnemonic: CS → Chandrababu → 58 year old |
ㅤ | Activates tPA → Plasminogen → Plasmin (Fibrinolysin) → Fibrinolysis |
Heparin-like molecule | Produced by endothelium |
ㅤ | Binds Antithrombin III |
ㅤ | Inactivates 2, 9, 10, 11, 12 |
Tissue Factor Pathway Inhibitor (TFPI) | ⛔ Tissue Factor → 3 |
ㅤ | ⛔ TF – Factor 7 interaction |
ㅤ | ⛔ Factor 7 |
ㅤ | ⛔ Factor Xa formation |
Factors Regulating Anticoagulation Pathways
- Plasminogen activator inhibitor
- Alpha 2 antiplasmin
- Thrombin activatable fibrinolysis inhibitor
Role of Vitamin K in Coagulation

- Acts as a coenzyme for
- gamma carboxylation /
- post translational carboxylation.
- This activates:
- Clotting Factors 2, 7, 9 & 10.
- Protein C & S.
- Osteocalcin.
- Inactive Epoxide form → Active hydroquinone form of Vitamin K
- by Epoxide reductase.
Warfarin
- ⛔Epoxide reductase
- ⇏ Vitamin K active form
- ⛔ gamma carboxylase ⇏ γ carboxyglutamic acid
- Prevent activation of
- 2, 7, 9, 10
- Order of decline (fastest → slowest)
- 7 > 9 > 10 > 2
- Protein C & protein S
- Responsible for Prothrombotic action initial days
- Oral anticoagulant
- Takes 4-5 days to produce action
- Mainly used for maintenance purpose
- Contraindicated in pregnancy →
- Effect of Warfarin is monitored by PT/INR
- Target INR for Post valve replacement: 2.5 - 3.5

Megakaryocyte





- Precursor or "mother" of platelets.
- Multi-nucleated cell.
Associated Disorder | Megakaryocyte Appearance | Mnemonic / Note |
Essential Thrombocythemia (ET) | Staghorn | • Staghorn → sET |
Myelodysplastic Syndrome (MDS) | Pawn ball | • Monosomy 7 in children • 5q deletion in adults • MD → Paul |
Primary Myelofibrosis | Cloud-like | • Cloud fibre |
Chronic Myeloid Leukemia (CML) | Dwarf | • "CML" sounds like "small" |
Normal Platelet Count and Function

- Normal platelet count: 1.5 to 4.5 lakhs per mm cube.
- Normal function: To make a blood clot.
- Normal platelet adhesion is prevented by endothelium.
Steps of Blood Clot Formation





- Tikka (Ticagrelor) in a Can (Cangrelor) → Reversible
- PAR-1 (Protease Activator Receptor) INHIBITOR:
- AtoPaxar
- VoraPaxar





- Process:
- Vasoconstriction → Platelet Adhesion → Platelet Secretion → Platelet Aggregation → Clotting System ++
1. Vasoconstriction

- Temporary stop in blood flow.
- Mediators:
- Serotonin (from platelets)
- Endothelin
2. Platelet Adhesion
- Occurs at injury site.
- Endothelial injury → Subendothelium exposed → releases large numbers of high molecular weight vWF → Blood hits vWF → conformational change in vWF.
vWF binds to | Collagen Receptor | Platelet Receptor |
via | gp6 | gp1b9 |
- vWF globular form → Converted to Filamentous form.
- Mnemonic:
- "111 makes it step number one"
- GP 1B9 binds to 1 von Willebrand factor for step number 1)
3. Platelet Activation
- Conformational changes
4. Platelet Secretion
- Platelets release granule contents.
- Two types of granules present:
- Alpha granules
- Delta granules
- Alpha granules:
- Release most contents
- Examples:
- P-selectin, vWF, Platelet Factor 4, PDGF, Factor 5, Factor 8, Fibrinogen, Fibronectin
- Release "P" and "F" (factor) related substances.
- HIT is against Platelet factor 4
- Delta granules (or Dense granules):
- Mnemonic: "DENSE CASHE"
- Serum Calcium
- Adenosine (ADP, ATP)
- Serotonin
- Histamine
- Epinephrine

5. Platelet Aggregation

- Platelets stick to each other.
- Requires:
- GP2B3A receptors on platelets.
- Fibrinogen linking platelets.
- Platelet plug is the primary hemostatic plug.
- Mnemonic: For steps after 2 and 3, use receptor GP2B3A
6. Activation of Clotting System (Secondary Hemostatic Plug)

- Platelets flip Phosphatidylserine (PS) to outside.
- Flipped PS has a negative charge.
- Negative charge activates clotting system → fibrinogen (from alpha granules) → Fibrin → forms stable blood clot → Secondary hemostatic plug.
The Clotting System Pathways




- Consists of intrinsic, extrinsic, and common pathways.
COAGULATION CASCADE
- Positive feedback
- Endothelial injury
- Lot of Tissue Factor (3) is produced
- In vivo, Extrinsic cascade > Intrinsic
- Factor 10a produced → activates intrinsic cascade
- by back amplification.
Pathways
- Extrinsic Pathway
- Activated by tissue injury (external).
- 7, 3
- Initiated by Tissue factor
- 3 → 3a
- 7 → 7a
- 3a + 7a + Ca → 10a (activate factor 10)
- "Calcium is at the connections".
- Mnemonic:
- 73 year old not in tour → external
- "7 + 3 is also 10".
- Intrinsic Pathway
- CONTACT ACTIVATION IN LABS
- 8, 9, 11, 12
- 12a → 11a → 9a → 8a + Calcium → 10a
- Mnemonic: 8th 9th 11th 12th in tour
- Initiated by negatively charged surfaces
- from phosphatidylserine
- Kininogen/Kallikrein
- Amplifies intrinsic pathway
- Common Pathway
- Starts after factor 10 activation
- 10 → 2 → 1
- 10a + 5 + Calcium + Phospholipid = 2a
- 2a + 13a + 5a = 1a
- Fibrin Stabilization
- Fibrin (1a) + 13a + Calcium → Stable clot
- Factor 1a
- Fibrin clot
- Factor 13:
- Laki-Lorand factor / fibrin stabilizing factor
ㅤ | Name | Deficincies | Mnemonic / Notes |
I | Fibrinogen | Afibrinogenemia | First → Fibrin |
II | Prothrombin | Hypoprothrombinemia (d/t vitamin K deficiency) | Before three → Prothrombin |
III | Tissue Thromboplastin | ㅤ | Three → Tissue Thromboplastin |
IV | Calcium (Ca²⁺) | ㅤ | ㅤ |
V | Proaccelerin | Parahemophilia | 5 gears in acceleration → Accelerin Hemophila ashutri kondu povan vandi acclerate cheyyunna aalu → Proaccelerin ⇔ Parahemophilia |
VII | Proconvertin | Hypoconvertinemia | Convert school in 7th |
VIII | Anti-hemophilic Factor A | Hemophilia A | • Factor 8 assay confirms • Rx: Give cryoprecipitate |
IX | Anti-hemophilic Factor B | Hemophilia B / Christmas disease | • Factor 9 assay confirms • Rx: Give FFP |
X | Stuart-Prower Factor | ㅤ | 10th → SSLC Power → Stuart Prower |
XI | Anti-hemophilic Factor C | Plasma thromboplastin antecedent (PTA) deficiency | ㅤ |
XII | Hageman Factor | Hageman triad | Age when 12th standard |
XIII | Fibrin Stabilizing Factor/ Laki Lorand Factor | ㅤ | Stabilise after 12th standard |
Diagnostic Tests for Bleeding Disorders
Test | Normal Value | Measures Primarily |
Platelet count | 1.5 - 4 lakhs cells/mm³ | ㅤ |
Bleeding Time | 2 to 9 minutes | Platelet quantity or function ”I clot in 6 mins but still bleed for 8 mins” |
Clotting Time | 8 to 15 minutes | Time for blood clot formation |
Thrombin Time (TT) | ㅤ | Fibrinogen (Factor 1) "TT first trimester" (TT → F1) |
Urea Clot Solubility | ㅤ | ㅤ |
Prothrombin Time (PT) | ㅤ | ㅤ |
↳ Features | 11 to 16 seconds | Extrinsic pathway "PET" (PT for Extrinsic pathway) |
↳ Substance used | ㅤ | • Kaolin → XII → XIIa • Cephalin (platelet phospholipids substitute) • Ca²⁺ |
↳ Defect/ deficiency | ㅤ | • VIII, IX, XI, XII, V, X, Fibrinogen, Prothrombin |
APTT | ㅤ | ㅤ |
↳ Features | 25 to 35 seconds | Intrinsic pathway |
↳ Substance used | ㅤ | • Exogenous tissue thromboplastin (Factor 3); • Ca²⁺ |
↳ Defect/ deficiency | ㅤ | • VII, V, X, Fibrinogen, Prothrombin |
- APTT and PT → in Light blue Vacutainer
- Mnemonic:
- APTT:
- Apt techaer
- Safeayitt (Cephalin) kondupovan (Kaolin) → tourinu (78,9,11,12)
- 2-4 days tour → 26 to 40 sec
- PT
- Part time → for 73 yr old
- 11:00 → 16:00 hrs → 11-16sec

Bleeding - Approach
1. Platelet Issues
- Bleeding time ↑

Decrease in number (Thrombocytopenia):
- Isolated: Often due to TTP, ITP.

Pancytopenia:
- Often due to Acute leukemia, Myelodysplastic syndrome (MDS), Aplastic anemia.
Functional issue of platelets:

Inherited:
- Bernard-Soulier Syndrome
- Defective GP 1B9 receptor.
- Abnormal Ristocetin
- Aggregation
- Giant platelets
- Mnemonic: "B for B" (Bernard-Soulier, Big platelets).
- Glanzmann's Thrombasthenia
- Defective GP2B3A receptor.
- Abnormal ADP/collagen
- Aggregation
- Mnemonic: To differentiate from Bernard-Soulier (GP1B9), "B comes first, G comes later".
- Alpha Granule Defect
- Known as Gray Platelet Syndrome.
- Mnemonic: "Alpha granule problem, aged white hair... Gray platelet syndrome".
- Delta Granule Defect
- Known as Hermansky-Pudlak Syndrome.
- A/w oculocutaneous albinism.
Acquired:
- CKD
- Drugs like ecospirin.

DIAGNOSTIC APPROACH


Bleeding can be due to | Features |
Platelet issue | Small bleed like Mucosal bleed |
Clotting factor | Hematoma, joint bleed |
1. Number
- Thrombocytopenia
- A/c → Child < 6m
- C/c → Old > 6m
2. Function
- PFA 100 analysis
- Platelet function analysis
- Best Screening Test
- Calculates aperture closing time
- (time for platelets to form a clot)
- Platelet Fault analysis
- (If prolonged → Defective platelet function)
- -ve → Normal (<80sec)
- +ve → Abnormal (>80sec)
If Abnormal PFA → RAT
- Ristocetin Agglutination Test
- Check adhesion: Adhesion factor
- Negative
- Adhesion defect → vWF, BS
- Add plasma
- Normalise → vwF (due to gain of factor 8)
- Check APTT
- ↑↑ → vwF
- Normal → BS
- Positive
- Normal adhesion
- So check aggregation
If RAT Positive → Secondary wave of aggregation

- Absent/defective waves → Aggregation defect → GT
- Waves partially normal → Activation defect → GP, HP
Level Affected | Defect | Disorder |
Adhesion | Gp Ib–IX defect ↳ Bernard–Soulier syndrome vWF defect ↳ von Willebrand disease | • Abnormal PFA • RAT Negative |
Activation | Alpha granule defect ↳ Grey platelet syndrome Delta granule defect ↳ Hermansky–Pudlak syndrome | • RAT Positive • Secondary wave of aggregation ↳ Waves partially normal |
Aggregation | Gp IIb–IIIa defect ↳ Glanzmann thrombasthenia | • RAT Positive • Secondary wave of aggregation ↳ Absent/defective waves |
Feature | BSS | Glanzmann |
Defect | Gp Ib–IX | Gp IIb–IIIa |
Key Features | Large platelets | ㅤ |
Problem | Adhesion defect (Ristocetin) | Aggregation defect (ADP / Collagen) |
Bleeds | Platelet bleeds | Severe bleeding ↳ Recurrent episodes ↳ Heavy menstrual bleeding |

• Do not Normalise on adding Risto
↳ Abnormal Ristocetin ⇒ BSS

• Abnormal ADP, Epinephrine, Collagen
↳ Aggregation defect ⇒ GT

↳ Grey platelet syndrome
↳ Hermansky–Pudlak syndrome
NOTE
- Blue → Normal sample
- Red → Patient sample
Plasma Used | Test |
PRP – Platelet-Rich Plasma | • Platelet aggregation studies |
PPP – Platelet-Poor Plasma | • PT / APTT / coagulation studies • Reference for 100% light transmission in Platelet aggregation |




- 51 (HLA B51) yr old Nolan (Anti enolase) on a Bus (behcets)



Condition | First-line | If Inhibitors Present |
Hemophilia A (↓ 8) | Factor VIII | rFVIIa or aPCC |
Hemophilia B (↓ 9) | Factor IX | rFVIIa or aPCC |
Factor 7 deficiency | rFVIIa | ㅤ |
- rF 7a or aPCC
- rFVIIa bypasses 8 & 9
Bypassing Agents
- Recombinant Factor VIIa (rFVIIa)
- Activates Factor X → Xa
- Bypasses factors VIII and IX
- Activated Prothrombin Complex Concentrate (aPCC / FEIBA)
- rFVIIa preferred when aPCC contraindicated (e.g., DIC risk).
Scenarios (Lab Test Interpretations)

Oozing from puncture sites d/d
- DIC
- Acute hemolytic transfusion reaction
Factor 12 deficiency
- Doesn’t cause bleeding in vivo
PT | APTT | Platelet Count | Likely Cause | Notes |
Normal | Increased | Normal | Factor XII, XI, IX, VIII deficiency | - Factor XII deficiency: no bleeding - Factor XI: mild bleeding - Factor VIII, IX: severe bleeding (Hemophilia A/B) |
Normal | Increased BT also ↑↑ | Normal | vWD (qualitative platelet defect) | Due to defective vWF → decreased Factor VIII carrying capacity |
Normal | Increased | Normal | High molecular weight kininogen or prekallikrein deficiency | No bleeding manifestations |
Normal | Increased | Normal | Antiphospholipid antibody syndrome | No bleeding, but thrombosis |
Prolonged | Normal | Normal | Extrinsic pathway defect (e.g., TF or Factor VII deficiency) | Warfarin inhibits Vitamin K → Factor VII; INR target: 2–3 |
Prolonged | Prolonged | Normal | Common pathway defect | May involve Factor V, X, prothrombin, fibrinogen Afibrinogenemia: most common |
Prolonged | Prolonged | Decreased | DIC (Disseminated Intravascular Coagulation) | Consumptive coagulopathy |
Hemostatic Disorders Summary
Disorder | Pathogenesis | PLC | BT | aPTT | PT | Extra |
Bernard-Soulier syndrome | Deficiency of GpIb-IX | Normal | ↑ | Normal | Normal | - Platelet aggregation with ristocetin: Abnormal |
ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | - Giant platelets |
Glanzmann's thrombasthenia | Deficiency of Gp IIb-IIIa | Normal | ↑ | Normal | Normal | - Platelet aggregation with ADP: Abnormal |
ITP | Antiplatelet antibodies (Type 2 HS reaction) | ↓ | ↑ | Normal | Normal | - BMA: Increased megakaryocytes |
ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | - P/S: Giant platelets |
HUS | E. coli O157:H7, Shigella | ↓ | ↑ | Normal | Normal | - Schistocytes |
ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | - Reticulocytes↑, LDH↑ |
TTP | Mutation of ADAMTS13 | ↓ | ↑ | Normal | Normal | - Schistocytes |
ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | - Reticulocytes↑, LDH↑ |
Hemophilia A | Factor VIII deficiency | Normal | Normal | ↑ | Normal | - Factor VIII↓ |
Hemophilia B | Factor IX deficiency | Normal | Normal | ↑ | Normal | - Factor IX↓ |
vWD | vWF deficiency | Normal | ↑ | ↑ | Normal | - Factor VIII↓ |
ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | ㅤ | - RIPA abnormal |
DIC | - Endothelial injury | ↓ | ↑ | ↑ | ↑ | - FDP↑ |
ㅤ | - Activation of coagulation & fibrinolytic system | ㅤ | ㅤ | ㅤ | ㅤ | - D-dimers↑ |
Vitamin K deficiency | Deficiency of factors: 2, 7, 9, 10 | Normal | Normal | ↑ | ↑ | - |
Vascular disorders | - | Normal | Normal | Normal | Normal | - |
Thromboelastography (TEG)



Significance
- Tests efficiency of the entire blood coagulation pathway.
- Evaluates:
- Clot formation (all phases).
- Fibrinolysis.
Thromboelastography Parameters


Parameter | Measure of | Depend on | Rx |
Reaction time (R) | Time from coagulation cascade initiation to initial clot formation. | ↓ Coagulation Factors Affected in warfarin therapy (clotting factors) | FFP |
Kinetic time (K) | Time from initial clot to specific clot firmness (20mm). | ↓ Fibrinogen Coagulation Factors | Cryo Fibrinogen |
Alpha angle | Rate of fibrin formation & cross-linking. | ↓ Fibrinogen Coagulation Factors | Cryo Fibrinogen |
Max amplitude (MA) | Maximum clot strength. | Platelets | Platelets DDAVP |
Lysis 30 (Ly 30) | Fibrinolysis at 30 mins after MA. | Fibrinolysis | TXA Amicar |
- React (R) freshly (FFP)
- Alpha (α) Run (Kinetic) → Cry (Cryo)
- MAP (Ma → P)
- Fibrinolysis → TXA
Von Willebrand Disease (VWD)
- Platelet + clotting factor defect → vWD..
- "Combo problem"


Key Exam Lines
- Most common inherited bleeding disorder = VWD.
- Most common type = Type 1
- Severe type & AR= Type 3
- Unique point: Bleeding time ↑ + aPTT ↑ (PT normal).
- Ristocetin test abnormal in VWD.
- Type 2N → AR
- mimics hemophilia A
- RIPA Normal
- vWF → Normal → BT Normal
- F8 release affected → aPTT ↑↑
Von Willebrand Factor (vWF)
Functions | Effect due to deficiency |
Binds to GP1B9 for platelet adhesion | Bleeding time ↑ |
Carrier of Factor 8 | APTT ↑ |
- Gene: Produced by the chromosome 12p gene.
- Storage:
- Stored in the sub endothelium inside Weibel Palade bodies.
- Structure:
- vWF initially produced as monomer.
- Disulphide bonds form multimers
- Released into circulation.
- Proteolyzed by ADAMTS 13 (vWF metalloproteinase)
- Platelet adhesion
- Endothelial injury → Subendothelium exposed → releases large numbers of high molecular weight vWF → Blood hits vWF → conformational change in vWF.
- vWF globular form → Converted to Filamentous form.
- Mnemonic:
- "111 makes it step number one"
- GP 1B9 binds to 1 von Willebrand factor for step number 1)
vWF binds to | Collagen Receptor | Platelet Receptor |
via | gp6 | gp1b9 |
Lab Findings
- ↑ Bleeding time (platelet adhesion defect).
- APTT prolonged (↓ FVIII)
- PT normal.
- Platelet count normal (except Type 2B ↓).
- Abnormal ristocetin-induced platelet aggregation (RIPA).
- RIPA → Normal in 2N
Diagnosis
- Gold standard:
- ↓↓ vWF antigen level
- ↓↓ Ristocetin cofactor activity
- ↓↓ Factor VIII activity
- vWF multimer analysis (for subtype classification).
Management of VWD
- TOC: vWF concentrates.
- DOC: Desmopressin
- (also called Diamino Dimethyl arginine vasopressin - DDAVP).
- Releases vWF and FVIII from endothelium.
- Useful in Type 1 (contraindicated in Type 2B).
- Also with anti-fibrinolytics (tranexamic acid) and cryoprecipitate
Idiopathic Thrombocytopenic Purpura (ITP)
- Immune-mediated platelet destruction
- Caused by autoantibodies against:
- Gp IIb-IIIa
- Impaired platelet release from megakaryocytes

Bone Marrow Evaluation
- Not routinely required
- If done:
- Increased megakaryocytes
- ↑ Megakaryocytic precursors

Clinical Presentation
- Common manifestations: Petechiae, Ecchymosis, Epistaxis.
- Usually normal on general physical examination.
- Absence of:
- Fever, Pallor, Jaundice.
- Splenomegaly
- Bleeding into joints.
- Lymphadenopathy

ITP Classification and Features
- Platelet count ↓
- due to antibodies against GP2B3A.
- Bleeding time ↑
Feature | Acute ITP | Chronic ITP |
Demographics | Seen in children | Seen in adults ↳ Female > Male |
History | Follows viral infection | No viral history |
ㅤ | Platelet Count < 50,000 | Platelet Count < 10,000 |
Duration | Self-limiting | Persists for > 6 months |
Treatment | No long-term treatment needed | • Requires steroids • Splenectomy |

Management of Adult ITP
- 1st episode of ITP
- If no significant bleeding
- Wait and watch
- 1st line treatment:
- Oral Prednisolone 2 mg/kg/day for 5-7 days.
- If there is no response → IV Ig or Anti-D.
- Relapsed Cases (2/3rd of patients):
- Steroids + Azathioprine.
- Refractory Cases
- Rituximab is considered if there is no response.
- Splenectomy in refractory cases.
- Fostamatinib
- Maintenance
- Thrombopoietin receptor agonists - TPO agonists
- Eltrombopag (Oral).
- Romiplostim (Subcutaneous injections).
- Avoid Platelet transfusion